A Phase 2 interventional study of INCB028050 and INCB028050 in Rheumatoid Arthritis, sponsored by Incyte Corporation. Completed at 49 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-04.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 15th largest by enrollment, is the only one that started in 2009, is one of 3 in phase 2, and was the 1st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying anti-rheumatic drug (DMARD) therapy including biologics were enrolled. Screening evaluations were performed within approximately 28 days of randomization. The duration of the study was 6 months with the primary endpoint assessed at 3 months. Eligible participants were randomly assigned to one of three doses (4, 7 or 10 mg QD) of INCB028050 (Baricitinib) or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INCB028050 4mg Once daily (QD)
Drug: INCB028050
INCB028050 7mg QD
Drug: INCB028050
INCB028050 10mg QD
Drug: INCB028050
Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.
Drug: Placebo
4 mg capsules QD
Also known as: Baricitinib
7 mg capsules QD
Also known as: Baricitinib
10 mg capsule QD
Also known as: Baricitinib
Placebo matching INCB028050 QD
The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement
The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.
Time frame: Week 12
Participants With at Least 1 Adverse Event From Baseline Through Week 12
Time frame: From Baseline through week 12
Participants With at Least 1 Adverse Event From Week 12 to Week 24
Time frame: Week 12 to Week 24
The Percentage of Participants Who Were Assigned to Active Treatment at Baseline Achieving ACR 20 Improvement at Week 24
The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.
Time frame: From Baseline to Week 24
The Percentage of Participants Achieving American College of Rheumatology (ACR) 50 Improvement at Week 12 and Week 24
The ACR 50 is defined as ≥ 50% improvement in tender joint count plus ≥ 50% improvement in swollen joint count plus ≥50% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.
Time frame: Week 12 and Week 24
The Percentage of Participants Achieving American College of Rheumatology (ACR) 70 Improvement at Week 12 and Week 24
The ACR 70 is defined as ≥ 70% improvement in tender joint count plus ≥ 70% improvement in swollen joint count plus ≥ 70% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.
Time frame: Week 12 and Week 24
The Percentage of Participants Achieving American College of Rheumatology (ACR) 90 Improvement at Week 12 and Week 24
The ACR 90 is defined greater than or equal to (\>=) 90 percent (%) improvement in painful and tender joint count; \>= 90% improvement in swollen joint count; and \>= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP) at each visit.
Time frame: Week 12 and Week 24
Change in Disease Activity Score 28 (DAS28) CRP Score From Baseline at Week 12 and Week 24
Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus C-reactive protein (CRP). A higher score indicated more disease activity. The mean change from baseline (which represent decreases in the DAS 28 CRP scores) are shown as positive numbers in these analyses. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
Time frame: Baseline, Week 12 and Week 24
Change in Disease Activity Score 28 (DAS28) ESR Score From Baseline at Week 12 and Week 24
Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus Erythrocyte sedimentation rate (ESR). The DAS28-ESR is expressed as units on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR \<2.6. The mean change from baseline (which represent decreases in the DAS 28 ESR scores) are shown as positive numbers in these analyses.
Time frame: Baseline, Week 12 and Week 24
Percentage of Participants Achieving Low Disease Activity by DAS28 (ESR)≤3.2
Participants who achieved low disease activity based on the DAS 28 ESR (score ≤3.2). Participants who achieved low disease activity were classified as responders in this analysis.
Time frame: Week 12 and Week 24
Percentage of Participants Achieving Remission by DAS28 (ESR) ≤2.6
Participants who achieved inactive disease based on the DAS 28 ESR (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.
Time frame: Week 12 and Week 24
Percentage of Participants Achieving Remission by DAS28 (CRP) ≤2.6
Participants who achieved inactive disease based on DAS 28 CRP (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.
Time frame: Week 12 and Week 24
Change in ACR Assessment Tender Joint Count (TJC) From Baseline to Week 12 and Week 24
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Time frame: Baseline, Week 12 and Week 24
Change in ACR Assessment Swollen Joint Count (SJC) From Baseline to Week 12 and Week 24
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Time frame: Baseline, Week 12 and Week 24
Change in Participants' Assessment of Pain From Baseline at Week 12 and Week 24
Participants were to assess their current level of pain on a 100 mm horizontal Visual Analog Scale (VAS). The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain".
Time frame: Baseline, Week 12 and Week 24
Change in Participants' Global Assessment of Disease Activity From Baseline at Week 12 and Week 24
Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.
Time frame: Baseline, Week 12 and Week 24
Change in Physician's Global Assessment of Disease Activity (PGA) From Baseline at Week 12 and Week 24
Physicians were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.
Time frame: Baseline, Week 12 and Week 24
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline at Week 12 and Week 24
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Week 12 and Week 24
Change in Erythrocyte Sedimentation Rate (ESR) From Baseline at Week 12 and Week 24
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter/hour (mm/hr). A higher rate is consistent with inflammation.
Time frame: Baseline, Week 12 and Week 24
Change in C-reactive Protein (CRP) From Baseline at Week 12 and Week 24
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline, Week 12 and Week 24
Change in Duration of Morning Stiffness From Baseline at Week 12 and Week 24
Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes was recorded).
Time frame: Baseline, Week 12 and Week 24
Percentage of Participants Achieving Good European League Against Rheumatism (EULAR) Response (DAS28 ESR) at Week 12
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.
Time frame: Week 12
Percentage of Participants Achieving Good EULAR Response (DAS28ESR) at Week 24
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.
Time frame: Week 24
Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 12
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.
Time frame: Week 12
Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 24
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.
Time frame: Week 24
Change in SF-36 Mental Component Summary From Baseline at Week 12 and Week 24
The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").
Time frame: Baseline, Week 12 and Week 24
Change in SF-36 Physical Component Summary From Baseline at Week 12 and Week 24
The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").
Time frame: Baseline, Week 12 and Week 24
Percent of Participants Achieving a Minimum Clinically Important Difference (MCID) in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 and Week 24
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The MCID score for HAQ-DI is -0.22.
Time frame: Week 12 and Week 24
Percent of Participants Achieving a MCID in the Pain Score (Participant's Assessment of Pain) at Week 12 and Week 24
Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain". MCID for the pain score is a decrease of at least 10 mm on a 100 mm scale.
Time frame: Week 12 and Week 24
Percent of Participants Achieving a MCID in the SF-36 Physical Components and Mental Components at Week 12 and Week 24
The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").
Time frame: Week 12 and Week 24
The study population included participants diagnosed with RA who had failed to respond adequately to any DMARD therapy, including biologics.
| Milestone | Placebo | Placebo Crossing Over to 7 mg INCB028050 QD | Placebo Crossing Over to 10 mg INCB028050 QD | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|---|---|
| Started | 31 | 0 | 0 | 32 | 32 | 32 |
| Safety evaluable participants | 31 | 0 | 0 | 31 | 32 | 31 |
| Modified intent-to-treat participants | 31 | 0 | 0 | 31 | 32 | 30 |
| Completed | 29 | 0 | 0 | 29 | 30 | 27 |
| Not completed | 2 | 0 | 0 | 3 | 2 | 5 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Consent withdrawn | 1 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Corrected qt (qtc) exclusion criteria | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Placebo | Placebo Crossing Over to 7 mg INCB028050 QD | Placebo Crossing Over to 10 mg INCB028050 QD | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|---|---|
| Started | 0 | 14 | 15 | 29 | 30 | 27 |
| Completed | 0 | 14 | 13 | 27 | 29 | 24 |
| Not completed | 0 | 0 | 2 | 2 | 1 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Consent withdrawn | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo | Placebo Crossing Over to 7 mg INCB028050 QD | Placebo Crossing Over to 10 mg INCB028050 QD | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|---|---|
| Started | 0 | 14 | 13 | 27 | 29 | 24 |
| Safety evaluable participants | 0 | 14 | 15 | 29 | 30 | 27 |
| Completed | 0 | 14 | 13 | 26 | 29 | 24 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.
| Participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement | 10 | 16 | 19 | 16 |
| Participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Participants With at Least 1 Adverse Event From Baseline Through Week 12 | 19 | 15 | 20 | 23 |
| Participants | Placebo Crossing Over to 7 mg INCB028050 QD | Placebo Crossing Over to 10 mg INCB028050 QD | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|---|
| Participants With at Least 1 Adverse Event From Week 12 to Week 24 | 6 | 5 | 12 | 16 | 16 |
The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.
| Participants | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|
| The Percentage of Participants Who Were Assigned to Active Treatment at Baseline Achieving ACR 20 Improvement at Week 24 | 18 | 20 | 18 |
The ACR 50 is defined as ≥ 50% improvement in tender joint count plus ≥ 50% improvement in swollen joint count plus ≥50% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Week 12 | 13.0 | 35.0 | 31.0 | 30.0 |
| Week 24 | NA | 33.0 | 37.0 | 44.0 |
The ACR 70 is defined as ≥ 70% improvement in tender joint count plus ≥ 70% improvement in swollen joint count plus ≥ 70% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Week 12 | 3.0 | 16.0 | 9.0 | 10.0 |
| Week 24 | NA | 26.0 | 30.0 | 28.0 |
The ACR 90 is defined greater than or equal to (\>=) 90 percent (%) improvement in painful and tender joint count; \>= 90% improvement in swollen joint count; and \>= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP) at each visit.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Week 12 | 0.0 | 3.0 | 0.0 | 3.0 |
| Week 24 | NA | 11.0 | 10.0 | 12.0 |
Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus C-reactive protein (CRP). A higher score indicated more disease activity. The mean change from baseline (which represent decreases in the DAS 28 CRP scores) are shown as positive numbers in these analyses. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
| Units on a scale | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 5.71 ± 0.875 | 5.64 ± 1.098 | 5.76 ± 0.925 | 5.64 ± 0.774 |
| Change from baseline at Week 12 | -1.01 ± 1.245 | -1.87 ± 1.231 | -1.83 ± 1.534 | -1.84 ± 1.143 |
| Change from baseline at Week 24 | NA ± NA | -2.13 ± 1.355 | -2.23 ± 1.548 | -2.75 ± 1.234 |
Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus Erythrocyte sedimentation rate (ESR). The DAS28-ESR is expressed as units on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR \<2.6. The mean change from baseline (which represent decreases in the DAS 28 ESR scores) are shown as positive numbers in these analyses.
| Units on a scale | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 6.56 ± 0.840 | 6.41 ± 1.024 | 6.35 ± 0.968 | 6.37 ± 0.851 |
| Change from baseline at Week 12 | -1.25 ± 1.489 | -1.87 ± 1.342 | -1.97 ± 1.613 | -1.90 ± 1.481 |
| Change from baseline at Week 24 | NA ± NA | -2.17 ± 1.524 | -2.29 ± 1.455 | -2.79 ± 1.394 |
Participants who achieved low disease activity based on the DAS 28 ESR (score ≤3.2). Participants who achieved low disease activity were classified as responders in this analysis.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Week 12 | 19.0 | 23.0 | 31.0 | 13.0 |
| Week 24 | NA | 48.0 | 53.0 | 65.0 |
Participants who achieved inactive disease based on the DAS 28 ESR (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.
| percentage of participants | Placebo to INCB028050 7 mg QD | Placebo to INCB028050 10 mg QD | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|---|
| Week 12 | 6.7 | 18.8 | 16.0 | 19.0 | 7.0 |
| Week 24 | 21.4 | 23.1 | 22.0 | 27.0 | 26.0 |
Participants who achieved inactive disease based on DAS 28 CRP (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.
| percentage of participants | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|
| Week 12 | 23.0 | 25.0 | 17.0 |
| Week 24 | 30.0 | 40.0 | 48.0 |
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
| Tender joints | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 15.9 ± 6.67 | 14.4 ± 6.58 | 14.7 ± 6.70 | 15.9 ± 6.37 |
| Change from baseline at Week 12 | -5.3 ± 6.40 | -7.4 ± 6.21 | -6.4 ± 7.98 | -8.8 ± 8.86 |
| Change from baseline at Week 24 | NA ± NA | -8.3 ± 6.17 | -8.7 ± 7.42 | -12.0 ± 8.19 |
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
| Swollen joints | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 11.0 ± 5.28 | 12.0 ± 5.48 | 10.6 ± 4.57 | 12.9 ± 5.12 |
| Change from baseline at Week 12 | -3.7 ± 4.02 | -6.1 ± 4.43 | -5.4 ± 5.85 | -7.2 ± 5.57 |
| Change from baseline at Week 24 | NA ± NA | -7.3 ± 5.14 | -6.2 ± 5.04 | -9.1 ± 5.10 |
Participants were to assess their current level of pain on a 100 mm horizontal Visual Analog Scale (VAS). The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain".
| millimeter (mm) | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 62.37 ± 21.079 | 57.08 ± 24.716 | 63.25 ± 18.656 | 57.00 ± 22.995 |
| Change from baseline at Week 12 | -6.24 ± 22.065 | -21.98 ± 26.275 | -22.19 ± 25.631 | -22.97 ± 37.691 |
| Change from baseline at Week 24 | NA ± NA | -22.13 ± 27.294 | -27.62 ± 25.015 | -30.39 ± 30.847 |
Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.
| millimeter (mm) | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 66.19 ± 20.522 | 59.02 ± 26.314 | 69.69 ± 18.893 | 62.25 ± 21.346 |
| Change from baseline at Week 12 | -8.61 ± 22.569 | -22.06 ± 27.366 | -27.41 ± 21.990 | -25.48 ± 32.879 |
| Change from baseline at Week 24 | NA ± NA | -24.02 ± 26.921 | -31.53 ± 23.891 | -34.08 ± 27.518 |
Physicians were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.
| millimeter (mm) | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 63.45 ± 16.903 | 61.94 ± 19.162 | 59.80 ± 17.185 | 59.32 ± 16.890 |
| Change from baseline at Week 12 | -20.23 ± 19.824 | -33.87 ± 24.283 | -29.95 ± 25.741 | -30.88 ± 19.334 |
| Change from baseline at Week 24 | NA ± NA | -38.78 ± 22.527 | -36.94 ± 21.235 | -38.94 ± 21.776 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| Score on a scale | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 1.61 ± 0.494 | 1.50 ± 0.601 | 1.67 ± 0.474 | 1.50 ± 0.590 |
| Change from baseline at Week 12 (n=31, 31, 30, 30) | -0.20 ± 0.367 | -0.38 ± 0.568 | -0.48 ± 0.613 | -0.33 ± 0.539 |
| Change from baseline at Week 24 | NA ± NA | -0.56 ± 0.673 | -0.63 ± 0.563 | -0.39 ± 0.469 |
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter/hour (mm/hr). A higher rate is consistent with inflammation.
| mm/hr | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 40.8 ± 15.40 | 42.8 ± 17.62 | 37.3 ± 21.56 | 34.8 ± 29.05 |
| Change from baseline at Week 12 | -6.1 ± 15.76 | -7.5 ± 23.17 | -10.7 ± 21.52 | -5.9 ± 32.35 |
| Change from baseline at Week 24 | NA ± NA | -11.5 ± 21.96 | -12.8 ± 20.74 | -11.1 ± 26.00 |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
| mg/L | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 10.89 ± 11.556 | 15.63 ± 17.327 | 15.64 ± 16.113 | 7.52 ± 8.581 |
| Change from baseline at Week 12 | 0.18 ± 10.063 | -9.76 ± 16.053 | -4.01 ± 26.799 | -0.73 ± 13.488 |
| Change from baseline at Week 24 | NA ± NA | -6.74 ± 18.086 | -7.90 ± 16.713 | -5.52 ± 9.017 |
Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes was recorded).
| Minutes | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 78.5 ± 61.36 | 179.8 ± 347.48 | 125.5 ± 246.75 | 79.2 ± 56.83 |
| Change from baseline at Week 12 | 2.6 ± 69.23 | -51.1 ± 94.80 | -92.6 ± 250.51 | -42.2 ± 63.97 |
| Change from baseline at Week 24 | NA ± NA | -120.6 ± 245.35 | -99.3 ± 254.05 | -51.5 ± 70.84 |
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving Good European League Against Rheumatism (EULAR) Response (DAS28 ESR) at Week 12 | 19.0 | 23.0 | 31.0 | 13.0 |
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.
| percentage of participants | Placebo to INCB028050 7 mg QD | Placebo to INCB028050 10 mg QD | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Good EULAR Response (DAS28ESR) at Week 24 | 21.0 | 15.0 | 33.0 | 43.0 | 39.0 |
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 12 | 26.0 | 39.0 | 34.0 | 33.0 |
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.
| percentage of participants | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|
| Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 24 | 48.0 | 53.0 | 65.0 |
The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").
| scores on a scale | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 71.08 ± 27.534 | 69.03 ± 28.181 | 78.41 ± 30.329 | 78.62 ± 24.160 |
| Change from baseline at Week 12 | 2.92 ± 19.613 | 7.87 ± 19.547 | 2.21 ± 17.814 | 6.36 ± 25.203 |
| Change from baseline at Week 24 | NA ± NA | 7.72 ± 17.543 | 4.60 ± 17.146 | 2.29 ± 28.869 |
The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").
| scores on a scale | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Baseline | 29.14 ± 14.330 | 34.67 ± 16.006 | 26.71 ± 14.642 | 28.82 ± 14.212 |
| Change from baseline at Week 12 | 3.72 ± 11.027 | 9.57 ± 14.960 | 12.97 ± 17.932 | 8.35 ± 13.947 |
| Change from baseline at Week 24 | NA ± NA | 11.60 ± 14.503 | 15.56 ± 16.144 | 11.77 ± 13.387 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The MCID score for HAQ-DI is -0.22.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Week 12 (n=31, 31, 30, 30) | 45.0 | 61.0 | 63.0 | 43.0 |
| Week 24 | NA | 67.0 | 75.0 | 60.0 |
Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain". MCID for the pain score is a decrease of at least 10 mm on a 100 mm scale.
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Week 12 | 35.0 | 58.0 | 69.0 | 67.0 |
| Week 24 | NA | 59.0 | 70.0 | 72.0 |
The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").
| percentage of participants | Placebo | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD |
|---|---|---|---|---|
| Week 12 Physical Components | 52.0 | 68.0 | 69.0 | 57.0 |
| Week 24 Physical Components | NA | 67.0 | 77.0 | 76.0 |
| Week 12 Mental Components | 52.0 | 58.0 | 41.0 | 50.0 |
| Week 24 Mental Components | NA | 63.0 | 57.0 | 52.0 |
Collected over Screening through follow-up visit up to approximately 8 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Weeks 0-12) | — | 0/31 (0%) | 23/31 (74.2%) |
| INCB028050 4 mg QD (Weeks 0-12) | — | 0/31 (0%) | 19/31 (61.3%) |
| INCB028050 7 mg QD (Weeks 0-12) | — | 1/32 (3.1%) | 15/32 (46.9%) |
| INCB028050 10 mg QD (Weeks 0-12) | — | 0/31 (0%) | 20/31 (64.5%) |
| Placebo to INCB028050 7 mg QD | — | 0/14 (0%) | 11/14 (78.6%) |
| Placebo to INCB028050 10 mg QD | — | 0/15 (0%) | 9/15 (60%) |
| INCB028050 4 mg QD (Weeks 12-24) | — | 0/29 (0%) | 11/29 (37.9%) |
| INCB028050 7 mg QD (Weeks 12-24) | — | 1/30 (3.3%) | 17/30 (56.7%) |
| INCB028050 10 mg QD (Weeks 12-24) | — | 0/27 (0%) | 6/27 (22.2%) |
| Placebo to INCB028050 7 mg QD (After Week 24 to Week 28) | — | 0/14 (0%) | 0/14 (0%) |
| Placebo to INCB028050 10 mg QD (After Week 24 to Week 28) | — | 1/15 (6.7%) | 1/15 (6.7%) |
| INCB028050 4 mg QD (After Week 24 to Week 28) | — | 0/29 (0%) | 3/29 (10.3%) |
| INCB028050 7 mg QD (After Week 24 to Week 28) | — | 0/30 (0%) | 5/30 (16.7%) |
| INCB028050 10 mg QD (After Week 24 to Week 28) | — | 0/27 (0%) | 2/27 (7.4%) |
| Event | Placebo (Weeks 0-12) | INCB028050 4 mg QD (Weeks 0-12) | INCB028050 7 mg QD (Weeks 0-12) | INCB028050 10 mg QD (Weeks 0-12) | Placebo to INCB028050 7 mg QD | Placebo to INCB028050 10 mg QD | INCB028050 4 mg QD (Weeks 12-24) | INCB028050 7 mg QD (Weeks 12-24) | INCB028050 10 mg QD (Weeks 12-24) | Placebo to INCB028050 7 mg QD (After Week 24 to Week 28) | Placebo to INCB028050 10 mg QD (After Week 24 to Week 28) | INCB028050 4 mg QD (After Week 24 to Week 28) | INCB028050 7 mg QD (After Week 24 to Week 28) | INCB028050 10 mg QD (After Week 24 to Week 28) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/31 | 0/31 | 0/32 | 0/31 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 | 0/14 | 1/15 | 0/29 | 0/30 | 0/27 |
| Mallory-Weiss syndromeGastrointestinal disorders | 0/31 | 0/31 | 0/32 | 0/31 | 0/14 | 0/15 | 0/29 | 1/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| Erosive oesophagitisGastrointestinal disorders | 0/31 | 0/31 | 1/32 | 0/31 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| ThrombophlebitisVascular disorders | 0/31 | 0/31 | 1/32 | 0/31 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| Event | Placebo (Weeks 0-12) | INCB028050 4 mg QD (Weeks 0-12) | INCB028050 7 mg QD (Weeks 0-12) | INCB028050 10 mg QD (Weeks 0-12) | Placebo to INCB028050 7 mg QD | Placebo to INCB028050 10 mg QD | INCB028050 4 mg QD (Weeks 12-24) | INCB028050 7 mg QD (Weeks 12-24) | INCB028050 10 mg QD (Weeks 12-24) | Placebo to INCB028050 7 mg QD (After Week 24 to Week 28) | Placebo to INCB028050 10 mg QD (After Week 24 to Week 28) | INCB028050 4 mg QD (After Week 24 to Week 28) | INCB028050 7 mg QD (After Week 24 to Week 28) | INCB028050 10 mg QD (After Week 24 to Week 28) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BronchitisInfections and infestations | 1/31 | 1/31 | 2/32 | 1/31 | 2/14 | 0/15 | 0/29 | 0/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| PyrexiaGeneral disorders | 0/31 | 0/31 | 0/32 | 0/31 | 1/14 | 2/15 | 0/29 | 0/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| HeadacheNervous system disorders | 2/31 | 4/31 | 3/32 | 3/31 | 0/14 | 1/15 | 1/29 | 1/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| AnemiaBlood and lymphatic system disorders | 0/31 | 0/31 | 0/32 | 0/31 | 0/14 | 0/15 | 0/29 | 1/30 | 3/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| Herpes zosterInfections and infestations | 0/31 | 0/31 | 0/32 | 0/31 | 0/14 | 0/15 | 0/29 | 3/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| Upper respiratory tract infectionInfections and infestations | 3/31 | 2/31 | 2/32 | 1/31 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| SinusitisInfections and infestations | 2/31 | 1/31 | 3/32 | 1/31 | 1/14 | 0/15 | 0/29 | 1/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/31 | 0/31 | 3/32 | 1/31 | 0/14 | 1/15 | 1/29 | 2/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| VomitingGastrointestinal disorders | 0/31 | 0/31 | 0/32 | 0/31 | 1/14 | 0/15 | 0/29 | 2/30 | 2/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| InfluenzaInfections and infestations | 1/31 | 0/31 | 0/32 | 2/31 | 1/14 | 0/15 | 0/29 | 1/30 | 0/27 | 0/14 | 0/15 | 0/29 | 0/30 | 0/27 |
| Age, Continuous(years) | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 56.8 ± 12.28 | 53.7 ± 10.92 | 57.3 ± 10.38 | 55.2 ± 10.09 | 55.8 ± 10.92 |
| Sex: Female, Male(Participants) | INCB028050 4 mg QD | INCB028050 7 mg QD | INCB028050 10 mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Female | 29 | 26 | 25 | 22 | 102 |
| Male | 3 | 6 | 7 | 9 | 25 |
The record gives a start of May 2009, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 8 years 3 months after primary completion. A results delay was requested in Jun 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib